| Phase 14 trials |
|
Phase 1
|
NCT06662773 |
Nov 2024 → Mar 2025 overdue |
— |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06149611 |
Jan → Jun 2024 |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT05344729 |
Jul → Aug 2021 |
breast carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03850873 |
May 2019 → Sep 2021 |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT06851442 |
May → Nov 2025 |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT06202261 |
Apr 2023 → Dec 2026 expected |
breast carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05139082 |
Nov 2021 → Oct 2023 |
digestive system neoplasm |
Peking University |
Unknown
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT06702618 |
Feb 2025 → Jun 2026 overdue |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05496569 |
Aug 2022 → Jun 2024 |
dedifferentiated liposarcoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT05156450 |
Jan 2022 → Oct 2023 |
castration-resistant prostate carcinoma |
West China Hospital |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT04924192 |
Aug 2021 → Sep 2022 |
lung carcinoma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT04796623 |
Feb 2021 → May 2024 |
hormone receptor-positive breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT05780567 |
Mar 2023 → Dec 2026 expected |
breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05365178 |
Jul 2022 → Jul 2025 overdue |
hormone receptor-positive breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT05375461 |
Mar 2022 → Jan 2024 |
hormone receptor-positive breast cancer |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|